OncoMatch/Clinical Trials/NCT06755450
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Is NCT06755450 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies AUR112 for relapsed advanced lymphomas.
Treatment: AUR112 — A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy — NHL, CLL, or Hodgkin disease
patients must have relapsed or refractory to at least 2 prior lines of systemic therapies for NHL or CLL, or Hodgkin disease
Cannot have received: systemic anti-cancer therapy
Exception: Concomitant use of low dose prednisone (up to 10 mg/day) is allowed
Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study
Cannot have received: definitive radiotherapy
Exception: limited field palliative radiation is allowed
Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed)
Cannot have received: investigational agent
Use of any investigational agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1
Cannot have received: major surgery
Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia)
Lab requirements
Blood counts
ANC ≥ 1000/μL (without WBC growth factor support); Platelet count: For CLL ≥ 50,000/μL; For lymphomas ≥ 75,000/μL without bone marrow involvement and ≥ 50,000/μL with bone marrow involvement (without platelet transfusion support); Hemoglobin ≥ 9 g/dL (RBC transfusion allowed)
Kidney function
Creatinine clearance (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula)
Liver function
Total Bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN if Gilbert's syndrome); AST (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases); ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases)
Cardiac function
QTcF (Fridericia) interval >470 ms on ECG at screening and/or at Cycle 1 Day 1 pre-dose [excluded]; Uncontrolled congestive heart failure (NYHA Class 2-4), angina, MI, CVA, CABG, TIA, or PE within 3 months prior to Cycle 1 Day 1 [excluded]; Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1 [excluded]
Acceptable bone marrow and organ function at screening as described below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06755450 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-cancer therapy, definitive radiotherapy, investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify